Amneal is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $8.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Amneal's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Prolia Boncresa |
Amgen | Biosimilar | 2025 | FDA-approved 19 Dec 2025; interchangeable | $4.4B |
| Xgeva Oziltus |
Amgen | Biosimilar | 2025 | FDA-approved 19 Dec 2025; interchangeable | $2.1B |
| Opsumit | Johnson & Johnson | Generic | 2026 | FDA-approved 8 Jun 2026 | $2.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Amneal's share of it.
Amneal has FDA approval for Prolia, Xgeva and Opsumit, with no US launch confirmed. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.